Entrepreneurship / Innovation | Departement Biomedizin

Spin-offs und Start-ups

Das Departement Biomedizin fördert eine Kultur, in der wissenschaftliche Entwicklungen in der Medizintechnologie in kommerzielle Produkte überführt werden. Diese Aktivitäten spiegeln sich derzeit in einer stetig wachsenden Zahl von Spin-off-Unternehmen wider:

Bottneuro AG

Bottneuro develops a personalized Neuromodulation and EEG device for transcranial electrical stimulation (tES) at-home. By addressing the patients unique anatomy and pathophysiology, targeted, multifocal electrical stimulation can be applied to alter neuronal excitability and modulating the firing frequency of individual neurons. Highly specific modulation of endogenous brain activity opens the possibility of ‘’speaking the language of the brain’’. Dedicated brain areas and activity patterns are responsible for cognitive and executive functions and are altered by neurological and psychiatric diseases such as Alzheimer’s Disease, Dementia, Depression and Schizophrenia. Indicating the significant clinical potential for personalized tES in remote settings.

Cellec Biotek AG

CELLEC BIOTEK AG develops and commercializes bioreactor systems for 3D cell culture and tissue engineering. Thanks to the patented direct perfusion technologies, our products allow user-friendly seeding and functional maintenance of cells within porous materials. The resulting tissues are used as advanced models of development, physiology, pathology, and drug testing, and prospectively as engineered grafts for tissue and organ regeneration.

Cimeio Therapeutics

Cimeio is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ for patients with debilitating and life-threatening diseases. Cimeio's proprietary technology platform is based on the discovery of novel protein variants, which when inserted into cells allow them to preserve function while resisting depletion by a precisely paired immunotherapy. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

GeneGuide

GeneGuide AG uses a human genome-based approach to identify new drug targets and compounds for the treatment of neuropsychiatric disorders. In addition, the company also offers services in the following areas: 1. Target validation and specification, 2. Gene identification for pharmacogenetic purposes, 3. Proof-of-concept (PoC) clinical trials.

MindGuide, a division of GeneGuide, uses immersive technologies including next generation virtual reality and augmented reality to reduce anxiety, treat phobias and increase stress resilience.

Glycocalyx Therapeutics AG

A discovery & pre-clinical-stage company and a pioneer in the development of transformative pan-cancer therapies that target the tumor microenvironment removing barriers and inducing intra-tumoral immune architecture for effective full-circle immunotherapy. We focus on the discovery, design and engineering of catalytic immune effectors systems.

Hornet Therapeutics

Hornet Therapeutics is pioneering single gene-level precision engineering of immune cell metabolism to induce or abolish specific cellular states. The company is pre-clinical and focused on creating metabolically optimized cell backbones for CAR-T/NK cell therapies with improved long-term efficacy.

Our lead metabolic vulnerability asset provides the first-in-class potential to prevent a large group of virus-associated malignancies.

The company operates in stealth mode for now.

MPNquest

Founded in Switzerland as a spinoff of the University of Basel, we offer comprehensive in vivo efficacy studies for MPN, tailored to meet the unique needs of pharmaceutical companies worldwide. With a focus on Myeloproliferative Neoplasms (MPN), we provide cutting-edge research solutions to accelerate the development of novel therapeutics. Our commitment to excellence is rooted in scientific rigor, innovation, and a deep understanding of the complexities of MPN preclinical research.

Social Media